Visuals
Sidebar
Timing social distancing to avert unmanageable hospital surges
How can we best mitigate future pandemic waves while limiting collateral economic damage? As COVID-19 social distancing measures are relaxed ...
Funding allocation in 2020 predicts post-pandemic trends
If there is any doubt whether COVID-19 has changed the economy, simply look at the investment allocations for healthcare. The ...
Updated probability adjusted model predicts longer tail for herd immunity
More transmissible variants and slower rollout of vaccines increase downside risk to herd immunity timeline. Issues include manufacturing and supply ...
More cell and gene therapy start-ups than ever
Cell and gene therapies offer treatment, and sometimes cures, for patients with serious, often rare, and never-before-addressed diseases. And many ...
COVID-19: An Adaptive System
Systems thinking can help policymakers understand and influence the spread of infection and its multifaceted consequences across the community since ...
Path to Herd Immunity
COVID-19 Projections machine learning team cites the following notes in their live analysis of herd immunity in the United States. ...
COVID-19 in January 2021
We have an opportunity to reach the peak of this current wave by the end of January if we can ...
Daily Reported COVID-19 Cases
Europe seems to have turned the corner on their most recent upswing in cases. But if past patterns hold true, ...
IHME Timeline of Weekly Cases
Cases in the United States are increasing, and increasing at an unprecedented rate - portending an increase in the number ...
The Distribution of New Cases in the US has Shifted
The distribution of new cases in the US has shifted from the Northeast to the Southern and Western states. Pink ...
Projected Demand for Hospital Resources in Early 2021
Demand for hospital resources are likely to increase by the end of January 2021 - with a distinctly sharper rate ...
Aggregated COVID-19 Forecasts for November, 2020
The CDC received forecasts of COVID-19 deaths over the next 4 weeks in November from 47 modeling groups. Of the ...
BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us
Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...
Read morePopular
-
The Information Epidemic: How Digital Health Misinformation Is Rewiring Clinical Risk
-
Prevention Is Having a Moment and a Measurement Problem
-
Child Health Is Now a Platform Issue
-
Behavioral Health Is Now a Network Phenomenon
-
The Breach Is the Diagnosis: Cybersecurity Has Become a Clinical Risk Variable
